Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice

Autor: A. E. Karateev, Yu. V. Barysheva, Ya. V. Belokon, T. Yu. Bolshakova, Yu. Yu. Grabovetskaya, E. A. Dolzhenkova, L. N. Eliseeva, O. B. Ershova, E. V. Zonova, I. Yu. Chernova, A. O. Isakanova, M. N. Kirpikova, V. T. Komarov, E. V. Kryukova, A. I. Kulikov, D. I. Lakhin, L. A. Levasheva, L. V. Masneva, L. V. Menshikova, Yu. V. Mishina, S. V. Norina, Yu. N. Pashkovsky, A. V. Petrov, A. G. Rusanov, A. V. Sarapulova, K. A. Svodtseva, O. V. Semagina, A. N. Sudakova, S. N. Tkachenko, M. M. Toporkov, S. K. Tutelyan, G. R. Fadienko, O. S. Filonenko, O. P. Fomina, A. S. Chernov
Jazyk: ruština
Rok vydání: 2020
Předmět:
Zdroj: Современная ревматология, Vol 14, Iss 4, Pp 82-90 (2020)
Druh dokumentu: article
ISSN: 1996-7012
2310-158X
DOI: 10.14412/1996-7012-2020-4-82-90
Popis: A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands treatment options for OA therapy.Objective: to evaluate the efficacy and safety of Artroflex® that is a combination of chondroitin sulfate 400 mg and glucosamine sulfate 500 mg (CS + GS) to support joint health in patients with knee and/or hip OA.Patients and methods. When implementing an open observational research program, the results of using the CS + GS complex were assessed in 644 OA patients (74.7% women) (mean age, 58.0±14.6 years) who experienced moderate/severe pain and required to continuously take non-steroidal anti-inflammatory drugs (NSAIDs). The CS + GS complex was prescribed in a dose of 2 capsules per day for 3 months. The investigators estimated changes in pain on movement by a 0 to 10 verbal pain scale, general health (GH) by a 0–10 visual analogue scale), the Lequesne index, the need for NSAIDs, and patient satisfaction with treatment and its tolerance.Results and discussion. After 3-month therapy, there were decreases in pain intensity by 49.2±16.8%, GH scores by 45.6±18.1%, the Lequesne index from 9.0 [6.0; 13.0] to 5.0 [3.0; 9.0]; less than half (45.2%) of the patients still needed for NSAIDs. 82.2% of patients were satisfied or completely satisfied with treatment results; 89.6% reported good treatment tolerance.Adverse events (apparently associated with NSAID use) were recorded in 2.2% of cases. There were no serious complications that required CS + GS treatment discontinuation or hospitalization.Conclusion. The findings have indicated that Artroflex® used to support joint health is an effective agent that controls OA symptoms and has a good safety level.
Databáze: Directory of Open Access Journals
Externí odkaz: